Table 1.
Patient and clinical characteristics at study enrollment for the 124 triplets*
| Demographics | Case subjects (N = 124) | Control subjects (N = 248) | P† |
| Median age, y (interquartile range) | 64 (55.5–71) | 64 (54.5–70) | .612‡ |
| Median months HRT (interquartile range) | 0 (0–48) | 4 (0–120) | .014‡ |
| Median number pregnancies (interquartile range) | 2 (1–3) | 2 (1–3) | .317‡ |
| Race, No. (%) | |||
| White | 110 (89) | 230 (93) | .171 |
| Other | 13 (10) | 16 (6) | |
| Missing | 1 (1) | 2 (1) | |
| Stage, No (%) | |||
| I | 62 (50) | 96 (39) | .041 |
| II | 51 (41) | 140 (56) | |
| IIIA | 6 (5) | 10 (4) | |
| Missing | 5 (4) | 2 (1) | |
| Menopausal status at diagnosis§, No. (%) | |||
| Pre | 12 (10) | 36 (14) | .413 |
| Peri | 7 (5) | 12 (5) | |
| Post | 105 (85) | 200 (81) | |
| Adjuvant chemotherapy, No. (%) | |||
| Yes | 57 (46) | 130 (52) | .241 |
| No | 67 (54) | 118 (48) | |
| Type of clot, No (%) | |||
| DVT | 96 (77) | ||
| PE | 12 (10) | NA | |
| DVT and PE | 12 (10) | ||
| Arterial embolism | 3 (2) | ||
| Clotted line | 1 (1) | ||
| Clotting episode before tamoxifen treatment, No. (%) | |||
| Yes | 17 (14) | 12 (5) | .002 |
| No | 105 (85) | 236 (95) | |
| Missing | 2 (1) | 0 (0) | |
| Family history of thromboembolism, No. (%) | |||
| Yes | 25 (20) | 29 (12) | .055 |
| No | 76 (61) | 179 (72) | |
| Missing | 23 (19) | 40 (16) | |
| Smoked on treatment§, No. (%) | |||
| Yes | 19 (15) | 16 (6) | .019 |
| No | 101 (82) | 220 (89) | |
| Missing | 4 (3) | 12 (5) | |
*
DVT = deep vein thrombosis; HRT = hormone replacement therapy; NA = not applicable; PE = pulmonary thromboembolism.
†
All tests except where otherwise indicated were based on the χ2 statistic and were two-sided.
‡
Wilcoxon P values based on two-sided tests.
§
Menopause and smoking status were provided by patient at enrollment.